This page has only limited features, please log in for full access.
The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020. Of the patients studied, 59.5% showed a decrease (≥2 fold) in neutralizing antibody titer against B.1.1.7, 83.3% against P.1, and 90.5% against B.1.351 with respect to the original strain. The reduction in antibody titers against all analyzed variants, and in particular P.1 and B.1.351, suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.
Claudia Trombetta; Serena Marchi; Simonetta Viviani; Alessandro Manenti; Linda Benincasa; Antonella Ruello; Emilio Bombardieri; Ilaria Vicenti; Maurizio Zazzi; Emanuele Montomoli. Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. Viruses 2021, 13, 1347 .
AMA StyleClaudia Trombetta, Serena Marchi, Simonetta Viviani, Alessandro Manenti, Linda Benincasa, Antonella Ruello, Emilio Bombardieri, Ilaria Vicenti, Maurizio Zazzi, Emanuele Montomoli. Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. Viruses. 2021; 13 (7):1347.
Chicago/Turabian StyleClaudia Trombetta; Serena Marchi; Simonetta Viviani; Alessandro Manenti; Linda Benincasa; Antonella Ruello; Emilio Bombardieri; Ilaria Vicenti; Maurizio Zazzi; Emanuele Montomoli. 2021. "Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients." Viruses 13, no. 7: 1347.
Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the Covid−19 pandemic. By single cell sorting 4277 SARS−CoV−2 spike protein specific memory B cells from 14 Covid−19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. Up to 65,9% of monoclonals neutralized the wild type virus at a concentration of >500 ng/mL, 23,6% neutralized the virus in the range of 100 − 500 ng/mL and 9,1% had a neutralization potency in the range of 10 − 100 ng/mL. Only 1,4% neutralized the authentic virus with a potency of 1−10 ng/mL. We found that the most potent neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by antibodies that recognize the S1 domain, the S-protein trimeric structure and the S2 subunit. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS−CoV−2.
Emanuele Andreano; Emanuele Nicastri; Ida Paciello; Piero Pileri; Noemi Manganaro; Giulia Piccini; Alessandro Manenti; Elisa Pantano; Anna Kabanova; Marco Troisi; Fabiola Vacca; Dario Cardamone; Concetta De Santi; Linda Benincasa; Chiara Agrati; Maria Rosaria Capobianchi; Concetta Castilletti; Arianna Emiliozzi; Massimiliano Fabbiani; Francesca Montagnani; Lorenzo Depau; Jlenia Brunetti; Luisa Bracci; Emanuele Montomoli; Claudia Sala; Giuseppe Ippolito; Rino Rappuoli. Extremely potent human monoclonal antibodies from convalescent Covid-19 patients. 2020, 1 .
AMA StyleEmanuele Andreano, Emanuele Nicastri, Ida Paciello, Piero Pileri, Noemi Manganaro, Giulia Piccini, Alessandro Manenti, Elisa Pantano, Anna Kabanova, Marco Troisi, Fabiola Vacca, Dario Cardamone, Concetta De Santi, Linda Benincasa, Chiara Agrati, Maria Rosaria Capobianchi, Concetta Castilletti, Arianna Emiliozzi, Massimiliano Fabbiani, Francesca Montagnani, Lorenzo Depau, Jlenia Brunetti, Luisa Bracci, Emanuele Montomoli, Claudia Sala, Giuseppe Ippolito, Rino Rappuoli. Extremely potent human monoclonal antibodies from convalescent Covid-19 patients. . 2020; ():1.
Chicago/Turabian StyleEmanuele Andreano; Emanuele Nicastri; Ida Paciello; Piero Pileri; Noemi Manganaro; Giulia Piccini; Alessandro Manenti; Elisa Pantano; Anna Kabanova; Marco Troisi; Fabiola Vacca; Dario Cardamone; Concetta De Santi; Linda Benincasa; Chiara Agrati; Maria Rosaria Capobianchi; Concetta Castilletti; Arianna Emiliozzi; Massimiliano Fabbiani; Francesca Montagnani; Lorenzo Depau; Jlenia Brunetti; Luisa Bracci; Emanuele Montomoli; Claudia Sala; Giuseppe Ippolito; Rino Rappuoli. 2020. "Extremely potent human monoclonal antibodies from convalescent Covid-19 patients." , no. : 1.
The recent outbreak of a novel Coronavirus (SARS-CoV-2) and its rapid spread across the continents has generated an urgent need for assays to detect the neutralising activity of human sera or human monoclonal antibodies against SARS-CoV-2 spike protein and to evaluate the serological immunity in humans. Since the accessibility of live virus microneutralisation (MN) assays with SARS-CoV-2 is limited and requires enhanced bio-containment, the approach based on “pseudotyping” can be considered a useful complement to other serological assays. After fully characterising lentiviral pseudotypes bearing the SARS-CoV-2 spike protein, we employed them in pseudotype-based neutralisation assays in order to profile the neutralising activity of human serum samples from an Italian sero-epidemiological study. The results obtained with pseudotype-based neutralisation assays mirrored those obtained when the same panel of sera was tested against the wild type virus, showing an evident convergence of the pseudotype-based neutralisation and MN results. The overall results lead to the conclusion that the pseudotype-based neutralisation assay is a valid alternative to using the wild-type strain, and although this system needs to be optimised and standardised, it can not only complement the classical serological methods, but also allows serological assessments to be made when other methods cannot be employed, especially in a human pandemic context.
Inesa Hyseni; Eleonora Molesti; Linda Benincasa; Pietro Piu; Elisa Casa; Nigel J Temperton; Alessandro Manenti; Emanuele Montomoli. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses 2020, 12, 1011 .
AMA StyleInesa Hyseni, Eleonora Molesti, Linda Benincasa, Pietro Piu, Elisa Casa, Nigel J Temperton, Alessandro Manenti, Emanuele Montomoli. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses. 2020; 12 (9):1011.
Chicago/Turabian StyleInesa Hyseni; Eleonora Molesti; Linda Benincasa; Pietro Piu; Elisa Casa; Nigel J Temperton; Alessandro Manenti; Emanuele Montomoli. 2020. "Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays." Viruses 12, no. 9: 1011.